{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:56:12Z","timestamp":1791082572441,"version":"4.1.0"},"reference-count":170,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100019446","name":"Shandong Provincial Science and Technology Development Plan in the Field of Medical and Health","doi-asserted-by":"publisher","award":["202113050958"],"award-info":[{"award-number":["202113050958"]}],"id":[{"id":"10.13039\/501100019446","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"publisher","award":["2019YFE0-117800"],"award-info":[{"award-number":["2019YFE0-117800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Central Special Fund for Guiding Local Science and Technology Development","award":["YDZX2021117"],"award-info":[{"award-number":["YDZX2021117"]}]},{"DOI":"10.13039\/100014103","name":"Shandong Provincial Key R&D Plan","doi-asserted-by":"publisher","award":["2021SFGC1205"],"award-info":[{"award-number":["2021SFGC1205"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Heparin, as a glycosaminoglycan, is known for its anticoagulant and antithrombotic\nproperties for several decades. Heparin is a life-saving drug and is widely used for\nanticoagulation in medical practice. In recent years, there have been extensive studies\nthat heparin plays an important role in non-anticoagulant diseases, such as anti-inflammatory,\nanti-viral, anti-angiogenesis, anti-neoplastic, anti-metastatic effects, and so on. Clinical\nobservation and in vitro experiments indicate that heparin displays a potential multitarget\neffect. In this brief review, we will summarize heparin and its derivative's recently\nstudied progress for the treatment of various viral infections. The aim is to maximize the\nbenefits of drugs through medically targeted development, to meet the unmet clinical\nneeds of serious viral diseases<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867330666230203124032","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T06:31:40Z","timestamp":1677133900000},"page":"7-24","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Research Progress on Antiviral Activity of Heparin"],"prefix":"10.2174","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3168-9360","authenticated-orcid":true,"given":"Yi","family":"Wang","sequence":"first","affiliation":[{"name":"Chinese Materia Medica Pharmacology, Shandong Academy of Chinese Medicine, Jinan 250014, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shandong VeriSign Test Detection Co., LTD, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[{"name":"Chinese Materia Medica Pharmacology, Shandong Academy of Chinese Medicine, Jinan 250014, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyuan","family":"Jing","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Shandong\nUniversity of Traditional Chinese Medicine, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Hu","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Shandong\nUniversity of Traditional Chinese Medicine, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiushan","family":"Chen","sequence":"additional","affiliation":[{"name":"Zhenjiang Runjing High Purity Chemical Technology\nCo., Ltd., Zhenjiang, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"59","volume":"8","author":"Saikrushna J.","year":"2021","unstructured":"Saikrushna J.; Ram S.; Isolation, synthesis, and medicinal applications of heparin. Chem Biol Lett 2021,8(2),59-66","journal-title":"Chem Biol Lett"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"910743","DOI":"10.1155\/2013\/910743","volume":"2013","author":"Page C.","year":"2013","unstructured":"Page C.; Heparin and related drugs: beyond anticoagulant activity. ISRN Pharmacol 2013,2013,910743","journal-title":"ISRN Pharmacol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3390\/molecules22050749","volume":"22","author":"Lima M.","year":"2017","unstructured":"Lima M.; Rudd T.; Yates E.; New applications of heparin and other glycosaminoglycans. Molecules 2017,22(5),749-759","journal-title":"Molecules"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1007\/s00216-011-5367-7","volume":"401","author":"Zhang F.","year":"2011","unstructured":"Zhang F.; Yang B.; Ly M.; Solakyildirim K.; Xiao Z.; Wang Z.; Beaudet J.M.; Torelli A.Y.; Dordick J.S.; Linhardt R.J.; Structural characterization of heparins from different commercial sources. Anal Bioanal Chem 2011,401(9),2793-2803","journal-title":"Anal Bioanal Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/brv.12034","volume":"88","author":"Kamhi E.","year":"2013","unstructured":"Kamhi E.; Joo E.J.; Dordick J.S.; Linhardt R.J.; Glycosaminoglycans in infectious disease. Biol Rev Camb Philos Soc 2013,88(4),928-943","journal-title":"Biol Rev Camb Philos Soc"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/ph10040078","volume":"10","author":"Mohamed S.","year":"2017","unstructured":"Mohamed S.; Coombe D.; Heparin Mimetics: Their therapeutic potential. Pharmaceuticals (Basel) 2017,10(4),78-110","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0008-6215(00)80341-9","volume":"18","author":"Perlin A.S.","year":"1971","unstructured":"Perlin A.S.; Mackie D.M.; Dietrich C.P.; Evidence for a (1\u21924)-linked 4-O-(\u03b1-L-idopyranosyluronic acid 2-sulfate)-(2-deoxy-2-sulfoamino-D-glucopyranosyl 6-sulfate) sequence in heparin. Carbohydr Res 1971,18(2),185-194","journal-title":"Carbohydr Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fmed.2019.00016","volume":"6","author":"Vilanova E.","year":"2019","unstructured":"Vilanova E.; Vairo B.C.; Oliveira S.N.M.C.G.; Glauser B.F.; Capill\u00e9 N.V.; Santos G.R.C.; Tovar A.M.F.; Pereira M.S.; Mour\u00e3o P.A.S.; Heparins sourced from bovine and porcine mucosa gain exclusive monographs in the brazilian pharmacopeia. Front Med (Lausanne) 2019,6,16","journal-title":"Front Med (Lausanne)"},{"key":"ref=9","first-page":"901","volume":"23","author":"Zhang Z.","year":"2014","unstructured":"Zhang Z.; The structural characterization of low molecular weight heparin. Chin J New Drugs 2014,23(8),901-905+939","journal-title":"Chin J New Drugs"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/bs.pmbts.2019.02.003","volume":"163","author":"Hao C.","year":"2019","unstructured":"Hao C.; Sun M.; Wang H.; Zhang L.; Wang W.; Low molecular weight heparins and their clinical applications. Prog Mol Biol Transl Sci 2019,163,21-39","journal-title":"Prog Mol Biol Transl Sci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/jps.23501","volume":"102","author":"Fu L.","year":"2013","unstructured":"Fu L.; Li G.; Yang B.; Onishi A.; Li L.; Sun P.; Zhang F.; Linhardt R.J.; Structural characterization of pharmaceutical heparins prepared from different animal tissues. J Pharm Sci 2013,102(5),1447-1457","journal-title":"J Pharm Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/j.1365-2141.2008.07119.x","volume":"141","author":"Wardrop D.","year":"2008","unstructured":"Wardrop D.; Keeling D.; The story of the discovery of heparin and warfarin. Br J Haematol 2008,141(6),757-763","journal-title":"Br J Haematol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1021\/jm030176m","volume":"46","author":"Linhardt R.J.","year":"2003","unstructured":"Linhardt R.J.; Claude, S. Hudson award address in carbohydrate chemistry. Heparin: Structure and activity. J Med Chem 2003,46(13),2551-2564","journal-title":"J Med Chem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/ph9030038","volume":"9","author":"Oduah E.","year":"2016","unstructured":"Oduah E.; Linhardt R.; Sharfstein S.; Heparin: Past, present, and future. Pharmaceuticals (Basel) 2016,9(3),38-49","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0300-9084(01)01290-1","volume":"83","author":"Spillmann D.","year":"2001","unstructured":"Spillmann D.; Heparan sulfate: Anchor for viral intruders? Biochimie 2001,83(8),811-817","journal-title":"Biochimie"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/med.1026","volume":"22","author":"Liu J.","year":"2002","unstructured":"Liu J.; Thorp S.C.; Cell surface heparan sulfate and its roles in assisting viral infections. Med Res Rev 2002,22(1),1-25","journal-title":"Med Res Rev"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.antiviral.2015.01.008","volume":"116","author":"Hendricks G.L.","year":"2015","unstructured":"Hendricks G.L.; Velazquez L.; Pham S.; Qaisar N.; Delaney J.C.; Viswanathan K.; Albers L.; Comolli J.C.; Shriver Z.; Knipe D.M.; Kurt-Jones E.A.; Fygenson D.K.; Trevejo J.M.; Wang J.P.; Finberg R.W.; Heparin octasaccharide decoy liposomes inhibit replication of multiple viruses. Antiviral Res 2015,116,34-44","journal-title":"Antiviral Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.antiviral.2005.08.006","volume":"69","author":"Lee E.","year":"2006","unstructured":"Lee E.; Pavy M.; Young N.; Freeman C.; Lobigs M.; Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Antiviral Res 2006,69(1),31-38","journal-title":"Antiviral Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"e74035","DOI":"10.1371\/journal.pone.0074035","volume":"8","author":"Vervaeke P.","year":"2013","unstructured":"Vervaeke P.; Alen M.; Noppen S.; Schols D.; Oreste P.; Liekens S.; Sulfated Escherichia coli K5 polysaccharide derivatives inhibit dengue virus infection of human microvascular endothelial cells by interacting with the viral envelope protein E domain III. PLoS One 2013,8(8),e74035-e74047","journal-title":"PLoS One"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0092-8674(02)00660-8","volume":"108","author":"Kuhn R.J.","year":"2002","unstructured":"Kuhn R.J.; Zhang W.; Rossmann M.G.; Pletnev S.V.; Corver J.; Lenches E.; Jones C.T.; Mukhopadhyay S.; Chipman P.R.; Strauss E.G.; Baker T.S.; Strauss J.H.; Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002,108(5),717-725","journal-title":"Cell"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","volume":"496","author":"Bhatt S.","year":"2013","unstructured":"Bhatt S.; Gething P.W.; Brady O.J.; Messina J.P.; Farlow A.W.; Moyes C.L.; Drake J.M.; Brownstein J.S.; Hoen A.G.; Sankoh O.; Myers M.F.; George D.B.; Jaenisch T.; Wint G.R.W.; Simmons C.P.; Scott T.W.; Farrar J.J.; Hay S.I.; The global distribution and burden of dengue. Nature 2013,496(7446),504-507","journal-title":"Nature"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/nm0897-866","volume":"3","author":"Chen Y.","year":"1997","unstructured":"Chen Y.; Maguire T.; Hileman R.E.; Fromm J.R.; Esko J.D.; Linhardt R.J.; Marks R.M.; Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 1997,3(8),866-871","journal-title":"Nat Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1021\/jm000412i","volume":"44","author":"Marks R.M.","year":"2001","unstructured":"Marks R.M.; Lu H.; Sundaresan R.; Toida T.; Suzuki A.; Imanari T.; Hern\u00e1iz M.J.; Linhardt R.J.; Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors. J Med Chem 2001,44(13),2178-2187","journal-title":"J Med Chem"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0166-3542(02)00095-5","volume":"56","author":"Lin Y.L.","year":"2002","unstructured":"Lin Y.L.; Lei H.Y.; Lin Y.S.; Yeh T.M.; Chen S.H.; Liu H.S.; Heparin inhibits dengue-2 virus infection of five human liver cell lines. Antiviral Res 2002,56(1),93-96","journal-title":"Antiviral Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.antiviral.2005.02.001","volume":"66","author":"Talarico L.","year":"2005","unstructured":"Talarico L.; Pujol C.; Zibetti R.; Far\u00eda P.; Noseda M.; Duarte M.; Damonte E.; The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell. Antiviral Res 2005,66(2-3),103-110","journal-title":"Antiviral Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"9478","DOI":"10.1128\/JVI.05008-11","volume":"85","author":"Dalrymple N.","year":"2011","unstructured":"Dalrymple N.; Mackow E.R.; Productive dengue virus infection of human endothelial cells is directed by heparan sulfate-containing proteoglycan receptors. J Virol 2011,85(18),9478-9485","journal-title":"J Virol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.antiviral.2019.05.004","volume":"168","author":"Modhiran N.","year":"2019","unstructured":"Modhiran N.; Gandhi N.S.; Wimmer N.; Cheung S.; Stacey K.; Young P.R.; Ferro V.; Watterson D.; Dual targeting of dengue virus virions and NS1 protein with the heparan sulfate mimic PG545. Antiviral Res 2019,168,121-127","journal-title":"Antiviral Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2174\/2211352518999200429105342","volume":"19","author":"de Almeida M. M. C. S.","year":"2021","unstructured":"de Almeida M. M. C. S.; The crab heparin-like compound exhibits a strong inhibitory effect on infections by dengue virus-2. Anti-Infective Agents 2021,19(1),12-18","journal-title":"Anti-Infective Agents"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0035-9203(52)90042-4","volume":"46","author":"Dick G.W.A.","year":"1952","unstructured":"Dick G.W.A.; Kitchen S.F.; Haddow A.J.; Zika Virus (I). Isolations and serological specificity. Trans R Soc Trop Med Hyg 1952,46(5),509-520","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0035-9203(53)90021-2","volume":"47","author":"Dick G.W.A.","year":"1953","unstructured":"Dick G.W.A.; Paper: Epidemiological notes on some viruses isolated in Uganda (Yellow fever, Rift Valley fever, Bwamba fever, West Nile, Mengo, Semliki forest, Bunyamwera, Ntaya, Uganda S and Zika viruses). Trans R Soc Trop Med Hyg 1953,47(1),13-48","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1126\/science.aaf5316","volume":"352","author":"Sirohi D.","year":"2016","unstructured":"Sirohi D.; Chen Z.; Sun L.; Klose T.; Pierson T.C.; Rossmann M.G.; Kuhn R.J.; The 3.8 \u00c5 resolution cryo-EM structure of Zika virus. Science 2016,352(6284),467-470","journal-title":"Science"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMc1604449","volume":"374","author":"D\u2019Ortenzio E.","year":"2016","unstructured":"D\u2019Ortenzio E.; Matheron S.; de Lamballerie X.; Hubert B.; Piorkowski G.; Maquart M.; Descamps D.; Damond F.; Yazdanpanah Y.; Leparc-Goffart I.; Evidence of sexual transmission of zika virus. N Engl J Med 2016,374(22),2195-2198","journal-title":"N Engl J Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.virol.2019.01.019","volume":"529","author":"Gao H.","year":"2019","unstructured":"Gao H.; Lin Y.; He J.; Zhou S.; Liang M.; Huang C.; Li X.; Liu C.; Zhang P.; Role of heparan sulfate in the Zika virus entry, replication, and cell death. Virology 2019,529,91-100","journal-title":"Virology"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1080\/21645515.2017.1358325","volume":"13","author":"Maslow J.N.","year":"2017","unstructured":"Maslow J.N.; Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus. Hum Vaccin Immunother 2017,13(12),2918-2930","journal-title":"Hum Vaccin Immunother"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41586-018-0446-y","volume":"560","author":"Pierson T.C.","year":"2018","unstructured":"Pierson T.C.; Diamond M.S.; The emergence of Zika virus and its new clinical syndromes. Nature 2018,560(7720),573-581","journal-title":"Nature"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1021\/acs.biochem.6b01056","volume":"56","author":"Kim S.Y.","year":"2017","unstructured":"Kim S.Y.; Zhao J.; Liu X.; Fraser K.; Lin L.; Zhang X.; Zhang F.; Dordick J.S.; Linhardt R.J.; Interaction of Zika Virus envelope protein with glycosaminoglycans. Biochemistry 2017,56(8),1151-1162","journal-title":"Biochemistry"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.antiviral.2017.04.017","volume":"143","author":"Tan C.W.","year":"2017","unstructured":"Tan C.W.; Sam I.C.; Chong W.L.; Lee V.S.; Chan Y.F.; Polysulfonate suramin inhibits Zika virus infection. Antiviral Res 2017,143,186-194","journal-title":"Antiviral Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.antiviral.2016.12.023","volume":"140","author":"Ghezzi S.","year":"2017","unstructured":"Ghezzi S.; Cooper L.; Rubio A.; Pagani I.; Capobianchi M.R.; Ippolito G.; Pelletier J.; Meneghetti M.C.Z.; Lima M.A.; Skidmore M.A.; Broccoli V.; Yates E.A.; Vicenzi E.; Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells. Antiviral Res 2017,140,13-17","journal-title":"Antiviral Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1021\/acs.biochem.8b01267","volume":"58","author":"Kim S.Y.","year":"2019","unstructured":"Kim S.Y.; Koetzner C.A.; Payne A.F.; Nierode G.J.; Yu Y.; Wang R.; Barr E.; Dordick J.S.; Kramer L.D.; Zhang F.; Linhardt R.J.; Glycosaminoglycan compositional analysis of relevant tissues in zika virus pathogenesis and in vitro evaluation of heparin as an antiviral against zika virus infection. Biochemistry 2019,58(8),1155-1166","journal-title":"Biochemistry"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"442746","DOI":"10.1101\/2021.05.05.442746","volume":"2021","author":"Pagani I.","year":"2021","unstructured":"Pagani I.; Ottoboni L.; Podini P.; Ghezzi S.; Brambilla E.; Bezukladova S.; Corti D.; Bianchi M.E.; Capobianchi M.R.; Yates E.A.; Martino G.; Vicenzi E.; Heparin protects human neural progenitor cells from Zika Virus-induced cell death and preserves their differentiation into mature neural-glia cells. bioRxiv 2021,2021,442746","journal-title":"bioRxiv"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1517\/13543784.14.2.135","volume":"14","author":"Kleymann G.","year":"2005","unstructured":"Kleymann G.; Agents and strategies in development for improved management of herpes simplex virus infection and disease. Expert Opin Investig Drugs 2005,14(2),135-161","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ijos.2016.3","volume":"8","author":"Jiang Y.C.","year":"2016","unstructured":"Jiang Y.C.; Feng H.; Lin Y.C.; Guo X.R.; New strategies against drug resistance to herpes simplex virus. Int J Oral Sci 2016,8(1),1-6","journal-title":"Int J Oral Sci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S1473-3099(19)30470-0","volume":"20","author":"Looker K.J.","year":"2020","unstructured":"Looker K.J.; Welton N.J.; Sabin K.M.; Dalal S.; Vickerman P.; Turner K.M.E.; Boily M.C.; Gottlieb S.L.; Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data. Lancet Infect Dis 2020,20(2),240-249","journal-title":"Lancet Infect Dis"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/rmv.574","volume":"18","author":"Chou S.","year":"2008","unstructured":"Chou S.; Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol 2008,18(4),233-246","journal-title":"Rev Med Virol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1021\/acs.biomac.0c01789","volume":"22","author":"Pouyan P.","year":"2021","unstructured":"Pouyan P.; Nie C.; Bhatia S.; Wedepohl S.; Achazi K.; Osterrieder N.; Haag R.; Inhibition of herpes simplex virus type 1 attachment and infection by sulfated polyglycerols with different architectures. Biomacromolecules 2021,22(4),1545-1554","journal-title":"Biomacromolecules"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.coph.2008.07.002","volume":"8","author":"Lischka P.","year":"2008","unstructured":"Lischka P.; Zimmermann H.; Antiviral strategies to combat cytomegalovirus infections in transplant recipients. Curr Opin Pharmacol 2008,8(5),541-548","journal-title":"Curr Opin Pharmacol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2174\/187152609787847758","volume":"9","author":"Andrei G.","year":"2009","unstructured":"Andrei G.; De Clercq E.; Snoeck R.; Drug targets in cytomegalovirus infection. Infect Disord Drug Targets 2009,9(2),201-222","journal-title":"Infect Disord Drug Targets"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1128\/jvi.63.1.52-58.1989","volume":"63","author":"WuDunn D.","year":"1989","unstructured":"WuDunn D.; Spear P.G.; Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J Virol 1989,63(1),52-58","journal-title":"J Virol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"9106","DOI":"10.1128\/JVI.74.19.9106-9114.2000","volume":"74","author":"Trybala E.","year":"2000","unstructured":"Trybala E.; Liljeqvist J.A.; Svennerholm B.; Bergstr\u00f6m T.; Herpes simplex virus types 1 and 2 differ in their interaction with heparan sulfate. J Virol 2000,74(19),9106-9114","journal-title":"J Virol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1006\/viro.1995.1034","volume":"206","author":"Herold B.C.","year":"1995","unstructured":"Herold B.C.; Gerber S.I.; Polonsky T.; Belval B.J.; Shaklee P.N.; Holme K.; Identification of structural features of heparin required for inhibition of herpes simplex virus type 1 binding. Virology 1995,206(2),1108-1116","journal-title":"Virology"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1021\/bi800205t","volume":"47","author":"Copeland R.","year":"2008","unstructured":"Copeland R.; Balasubramaniam A.; Tiwari V.; Zhang F.; Bridges A.; Linhardt R.J.; Shukla D.; Liu J.; Using a 3-O-sulfated heparin octasaccharide to inhibit the entry of herpes simplex virus type 1. Biochemistry 2008,47(21),5774-5783","journal-title":"Biochemistry"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0092-8674(00)80058-6","volume":"99","author":"Shukla D.","year":"1999","unstructured":"Shukla D.; Liu J.; Blaiklock P.; Shworak N.W.; Bai X.; Esko J.D.; Cohen G.H.; Eisenberg R.J.; Rosenberg R.D.; Spear P.G.; A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 1999,99(1),13-22","journal-title":"Cell"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nchem.1073","volume":"3","author":"Hu Y.P.","year":"2011","unstructured":"Hu Y.P.; Lin S.Y.; Huang C.Y.; Zulueta M.M.L.; Liu J.Y.; Chang W.; Hung S.C.; Synthesis of 3-O-sulfonated heparan sulfate octasaccharides that inhibit the herpes simplex virus type 1 host\u2013cell interaction. Nat Chem 2011,3(7),557-563","journal-title":"Nat Chem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ejpb.2014.05.007","volume":"88","author":"Lembo D.","year":"2014","unstructured":"Lembo D.; Donalisio M.; Laine C.; Cagno V.; Civra A.; Bianchini E.P.; Zeghbib N.; Bouchemal K.; Auto-associative heparin nanoassemblies: A biomimetic platform against the heparan sulfate-dependent viruses HSV-1, HSV-2, HPV-16 and RSV. Eur J Pharm Biopharm 2014,88(1),275-282","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"10075","DOI":"10.3390\/ijms221810075","volume":"22","author":"Mese K.","year":"2021","unstructured":"Mese K.; Bunz O.; Volkwein W.; Vemulapalli S.P.B.; Zhang W.; Schellhorn S.; Heenemann K.; Rueckner A.; Sing A.; Vahlenkamp T.W.; Severing A.L.; Gao J.; Aydin M.; Jung D.; Bachmann H.S.; Z\u00e4nker K.S.; Busch U.; Baiker A.; Griesinger C.; Ehrhardt A.; Enhanced antiviral function of magnesium chloride-modified heparin on a broad spectrum of viruses. Int J Mol Sci 2021,22(18),10075-10088","journal-title":"Int J Mol Sci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"11948","DOI":"10.1039\/D1CC04703E","volume":"57","author":"Ahmadi V.","year":"2021","unstructured":"Ahmadi V.; Nie C.; Mohammadifar E.; Achazi K.; Wedepohl S.; Kerkhoff Y.; Block S.; Osterrieder K.; Haag R.; One-pot gram-scale synthesis of virucidal heparin-mimicking polymers as HSV-1 inhibitors. Chem Commun (Camb) 2021,57(90),11948-11951","journal-title":"Chem Commun (Camb)"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.ijbiomac.2021.05.107","volume":"183","author":"Jana S.","year":"2021","unstructured":"Jana S.; Mukherjee S.; Ribelato E.V.; Darido M.L.; Faccin-Galhardi L.C.; Ray B.; Ray S.; The heparin-mimicking arabinogalactan sulfates from Anogeissus latifolia gum: Production, structures, and anti-herpes simplex virus activity. Int J Biol Macromol 2021,183,1419-1426","journal-title":"Int J Biol Macromol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3390\/v13020352","volume":"13","author":"Bergeron H.C.","year":"2021","unstructured":"Bergeron H.C.; Murray J.; Nu\u00f1ez Castrejon A.M.; DuBois R.M.; Tripp R.A.; Respiratory syncytial virus (RSV) G protein vaccines with central conserved domain mutations induce CX3C-CX3CR1 blocking antibodies. Viruses 2021,13(2),352-368","journal-title":"Viruses"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12879-018-3002-3","volume":"18","author":"Chatzis O.","year":"2018","unstructured":"Chatzis O.; Darbre S.; Pasquier J.; Meylan P.; Manuel O.; Aubert J.D.; Beck-Popovic M.; Masouridi-Levrat S.; Ansari M.; Kaiser L.; Posfay-Barbe K.M.; Asner S.A.; Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study. BMC Infect Dis 2018,18(1),111","journal-title":"BMC Infect Dis"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1542\/pir.35.12.519","volume":"35","author":"Piedimonte G.","year":"2014","unstructured":"Piedimonte G.; Perez M.K.; Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev 2014,35(12),519-530","journal-title":"Pediatr Rev"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.1128\/AAC.02594-14","volume":"58","author":"Cagno V.","year":"2014","unstructured":"Cagno V.; Donalisio M.; Civra A.; Volante M.; Veccelli E.; Oreste P.; Rusnati M.; Lembo D.; Highly sulfated K5 Escherichia coli polysaccharide derivatives inhibit respiratory syncytial virus infectivity in cell lines and human tracheal-bronchial histocultures. Antimicrob Agents Chemother 2014,58(8),4782-4794","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3390\/v11070596","volume":"11","author":"Cagno V.","year":"2019","unstructured":"Cagno V.; Tseligka E.D.; Jones S.T.; Tapparel C.; Heparan sulfate proteoglycans and viral attachment: True receptors or adaptation bias? Viruses 2019,11(7),596","journal-title":"Viruses"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"6610","DOI":"10.1128\/JVI.73.8.6610-6617.1999","volume":"73","author":"Feldman S.A.","year":"1999","unstructured":"Feldman S.A.; Hendry R.M.; Beeler J.A.; Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J Virol 1999,73(8),6610-6617","journal-title":"J Virol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"6442","DOI":"10.1128\/JVI.74.14.6442-6447.2000","volume":"74","author":"Feldman S.A.","year":"2000","unstructured":"Feldman S.A.; Audet S.; Beeler J.A.; The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J Virol 2000,74(14),6442-6447","journal-title":"J Virol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"5278","DOI":"10.1128\/AAC.00771-12","volume":"56","author":"Donalisio M.","year":"2012","unstructured":"Donalisio M.; Rusnati M.; Cagno V.; Civra A.; Bugatti A.; Giuliani A.; Pirri G.; Volante M.; Papotti M.; Landolfo S.; Lembo D.; Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding peptide. Antimicrob Agents Chemother 2012,56(10),5278-5288","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s007050050156","volume":"142","author":"Krusat T.","year":"1997","unstructured":"Krusat T.; Streckert H.J.; Heparin-dependent attachment ofrespiratory syncytial virus (RSV) to host cells. Arch Virol 1997,142(6),1247-1254","journal-title":"Arch Virol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"10508","DOI":"10.1128\/JVI.74.22.10508-10513.2000","volume":"74","author":"Hallak L.K.","year":"2000","unstructured":"Hallak L.K.; Spillmann D.; Collins P.L.; Peeples M.E.; Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J Virol 2000,74(22),10508-10513","journal-title":"J Virol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1440-1797.2008.01012.x","volume":"13","author":"Guo Y.","year":"2008","unstructured":"Guo Y.; Wang Z.; Dong L.; Wu J.; Zhai S.; Liu D.; Ability of low-molecular-weight heparin to alleviate proteinuria by inhibiting respiratory syncytial virus infection. Nephrology (Carlton) 2008,13(7),545-553","journal-title":"Nephrology (Carlton)"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"e1005318","DOI":"10.1371\/journal.ppat.1005318","volume":"11","author":"Johnson S.M.","year":"2015","unstructured":"Johnson S.M.; McNally B.A.; Ioannidis I.; Flano E.; Teng M.N.; Oomens A.G.; Walsh E.E.; Peeples M.E.; Respiratory syncytial virus Uses CX3CR1 as a receptor on primary human airway epithelial cultures. PLoS Pathog 2015,11(12),e1005318-e1005333","journal-title":"PLoS Pathog"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1099\/vir.0.000218","volume":"96","author":"Chirkova T.","year":"2015","unstructured":"Chirkova T.; Lin S.; Oomens A.G.P.; Gaston K.A.; Boyoglu-Barnum S.; Meng J.; Stobart C.C.; Cotton C.U.; Hartert T.V.; Moore M.L.; Ziady A.G.; Anderson L.J.; CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells. J Gen Virol 2015,96(9),2543-2556","journal-title":"J Gen Virol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1128\/JVI.79.2.1113-1124.2005","volume":"79","author":"Zhang L.","year":"2005","unstructured":"Zhang L.; Bukreyev A.; Thompson C.I.; Watson B.; Peeples M.E.; Collins P.L.; Pickles R.J.; Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol 2005,79(2),1113-1124","journal-title":"J Virol"},{"key":"ref=72","first-page":"362","volume":"19","author":"William D.","year":"2020","unstructured":"William D.; James M.D.; Dirk M.; Elston M.D.; James R.; Treat M.D.; Misha A.; Rosenbach M.D.; Isaac M.; Neuhaus M.D.; Viral Diseases. Andrews' Diseases of the Skin 2020,19,362-420","journal-title":"Andrews' Diseases of the Skin"},{"key":"ref=73","first-page":"976","author":"Walker S.L.","year":"2020","unstructured":"Walker S.L.; Grayson W.; Human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS)-associated cutaneous diseases. McKee's Pathology of the Skin 2020,976-989.e5","journal-title":"McKee's Pathology of the Skin"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/aid.1993.9.167","volume":"9","author":"Patel M.","year":"1993","unstructured":"Patel M.; Yanagishita M.; Roderiquez G.; Bou-Habib D.C.; Oravecz T.; Hascall V.C.; Norcross M.A.; Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res Hum Retroviruses 1993,9(2),167-174","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0925-4439(92)90060-Z","volume":"1180","author":"Mbemba E.","year":"1992","unstructured":"Mbemba E.; Czyrski J.A.; Gattegno L.; The interaction of a glycosaminoglycan heparin, with HIV-1 major envelope glycoprotein. Biochim Biophys Acta Mol Basis Dis 1992,1180(2),123-129","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/BF02592355","volume":"26","author":"Howell A.L.","year":"1996","unstructured":"Howell A.L.; Taylor T.H.; Miller J.D.; Groveman D.S.; Eccles E.H.; Zacharski L.R.; Inhibition of HIV-1 infectivity by low molecular weight heparin. Int J Clin Lab Res 1996,26(2),124-131","journal-title":"Int J Clin Lab Res"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1093\/glycob\/8.2.131","volume":"8","author":"Harrop H.A.","year":"1998","unstructured":"Harrop H.A.; Rider C.C.; Heparin and its derivatives bind to HIV-1 recombinant envelope glycoproteins, rather than to recombinant HIV-1 receptor, CD4. Glycobiology 1998,8(2),131-137","journal-title":"Glycobiology"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"21353","DOI":"10.1074\/jbc.M500911200","volume":"280","author":"Viv\u00e8s R.R.","year":"2005","unstructured":"Viv\u00e8s R.R.; Imberty A.; Sattentau Q.J.; Lortat-Jacob H.; Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. J Biol Chem 2005,280(22),21353-21357","journal-title":"J Biol Chem"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0166-3542(92)90034-3","volume":"18","author":"Mohan P.","year":"1992","unstructured":"Mohan P.; Schols D.; Baba M.; De Clercq E.; Sulfonic acid polymers as a new class of human immunodeficiency virus inhibitors. Antiviral Res 1992,18(2),139-150","journal-title":"Antiviral Res"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1128\/AAC.01362-06","volume":"51","author":"Bugatti A.","year":"2007","unstructured":"Bugatti A.; Urbinati C.; Ravelli C.; De Clercq E.; Liekens S.; Rusnati M.; Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 Tat and gp120 proteins. Antimicrob Agents Chemother 2007,51(7),2337-2345","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s10529-011-0840-0","volume":"34","author":"Nassar R.A.","year":"2012","unstructured":"Nassar R.A.; Browne E.P.; Chen J.; Klibanov A.M.; Removing human immunodeficiency virus (HIV) from human blood using immobilized heparin. Biotechnol Lett 2012,34(5),853-856","journal-title":"Biotechnol Lett"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"5807","DOI":"10.1016\/j.febslet.2007.11.050","volume":"581","author":"Pasquato A.","year":"2007","unstructured":"Pasquato A.; Dettin M.; Basak A.; Gambaretto R.; Tonin L.; Seidah N.G.; Di Bello C.; Heparin enhances the furin cleavage of HIV-1 gp160 peptides. FEBS Lett 2007,581(30),5807-5813","journal-title":"FEBS Lett"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"15193","DOI":"10.1074\/jbc.M800066200","volume":"283","author":"Crublet E.","year":"2008","unstructured":"Crublet E.; Andrieu J.P.; Viv\u00e8s R.R.; Lortat-Jacob H.; The HIV-1 envelope glycoprotein gp120 features four heparan sulfate binding domains, including the co-receptor binding site. J Biol Chem 2008,283(22),15193-15200","journal-title":"J Biol Chem"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"e01005-17","DOI":"10.1128\/JVI.01005-17","volume":"91","author":"Plotnik D.","year":"2017","unstructured":"Plotnik D.; Guo W.; Cleveland B.; von Haller P.; Eng J.K.; Guttman M.; Lee K.K.; Arthos J.; Hu S.L.; Extracellular matrix proteins mediate HIV-1 gp120 interactions with \u03b1  \u03b2 . J Virol 2017,91(21),e01005-17","journal-title":"J Virol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"15768","DOI":"10.1038\/s41598-019-52201-w","volume":"9","author":"Bugatti A.","year":"2019","unstructured":"Bugatti A.; Paiardi G.; Urbinati C.; Chiodelli P.; Orro A.; Uggeri M.; Milanesi L.; Caruso A.; Caccuri F.; D\u2019Ursi P.; Rusnati M.; Heparin and heparan sulfate proteoglycans promote HIV-1 p17 matrix protein oligomerization: computational, biochemical and biological implications. Sci Rep 2019,9(1),15768-15779","journal-title":"Sci Rep"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMc2009324","volume":"382","author":"Meselson M.","year":"2020","unstructured":"Meselson M.; Droplets and aerosols in the transmission of SARS-CoV-2. N Engl J Med 2020,382(21),2063","journal-title":"N Engl J Med"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1126\/science.368.6489.356","volume":"368","author":"Wadman M.","year":"2020","unstructured":"Wadman M.; Couzin-Frankel J.; Kaiser J.; Matacic C.; A rampage through the body. Science 2020,368(6489),356-360","journal-title":"Science"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.7861\/clinmed.2020-0351","volume":"20","author":"Conzelmann C.","year":"2020","unstructured":"Conzelmann C.; M\u00fcller J.A.; Perkhofer L.; Sparrer K.M.J.; Zelikin A.N.; M\u00fcnch J.; Kleger A.; Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19. Clin Med (Lond) 2020,20(6),e218-e221","journal-title":"Clin Med (Lond)"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"e01987-20","DOI":"10.1128\/JVI.01987-20","volume":"95","author":"Tandon R.","year":"2021","unstructured":"Tandon R.; Sharp J.S.; Zhang F.; Pomin V.H.; Ashpole N.M.; Mitra D.; McCandless M.G.; Jin W.; Liu H.; Sharma P.; Linhardt R.J.; Effective inhibition of SARS-CoV-2 entry by heparin and enoxaparin derivatives. J Virol 2021,95(3),e01987-20","journal-title":"J Virol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","volume":"183","author":"Clausen T.M.","year":"2020","unstructured":"Clausen T.M.; Sandoval D.R.; Spliid C.B.; Pihl J.; Perrett H.R.; Painter C.D.; Narayanan A.; Majowicz S.A.; Kwong E.M.; McVicar R.N.; Thacker B.E.; Glass C.A.; Yang Z.; Torres J.L.; Golden G.J.; Bartels P.L.; Porell R.N.; Garretson A.F.; Laubach L.; Feldman J.; Yin X.; Pu Y.; Hauser B.M.; Caradonna T.M.; Kellman B.P.; Martino C.; Gordts P.L.S.M.; Chanda S.K.; Schmidt A.G.; Godula K.; Leibel S.L.; Jose J.; Corbett K.D.; Ward A.B.; Carlin A.F.; Esko J.D.; SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell 2020,183(4),1043-1057.e15","journal-title":"Cell"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"46","DOI":"10.11648\/j.ajasr.20200602.14","volume":"6","author":"Oppenheimer S.","year":"2020","unstructured":"Oppenheimer S.; Covid-19 pandemic, glycobiology, glycan shields, vaccine strategies, heparin sulfate: A mini review. Am J Appl Sci Res 2020,6(2),46-48","journal-title":"Am J Appl Sci Res"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3201\/eid1003.030683","volume":"10","author":"Vicenzi E.","year":"2004","unstructured":"Vicenzi E.; Canducci F.; Pinna D.; Mancini N.; Carletti S.; Lazzarin A.; Bordignon C.; Poli G.; Clementi M.; Coronaviridae and SARS-associated coronavirus strain HSR1. Emerg Infect Dis 2004,10(3),413-418","journal-title":"Emerg Infect Dis"},{"key":"ref=93","first-page":"971093v2","volume":"2020","author":"Mycroft-West C.","year":"2020","unstructured":"Mycroft-West C.; Su D.; Elli S.; Li Y.; Guimond S.; Miller G.; Turnbull J.; Yates E.; Guerrini M.; Fernig D.; Lima M.; Skidmore M.; The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1Receptor Binding Domain undergoes conformational change upon heparin binding. bioRxiv 2020,2020,971093v2","journal-title":"bioRxiv"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"066761","DOI":"10.1101\/2020.04.28.066761","volume":"2020","author":"Mycroft-West C.J.","year":"2020","unstructured":"Mycroft-West C.J.; Su D.; Pagani I.; Rudd T.R.; Elli S.; Guimond S.E.; Miller G.; Meneghetti M.C.Z.; Nader H.B.; Li Y.; Nunes Q.M.; Procter P.; Mancini N.; Clementi M.; Bisio A.; Forsyth N.R.; Turnbull J.E.; Guerrini M.; Fernig D.G.; Vicenzi E.; Yates E.A.; Lima M.A.; Skidmore M.A.; Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the surface protein (spike) S1 receptor binding domain with heparin. bioRxiv 2020,2020,066761","journal-title":"bioRxiv"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"104873","DOI":"10.1016\/j.antiviral.2020.104873","volume":"181","author":"Kim S.Y.","year":"2020","unstructured":"Kim S.Y.; Jin W.; Sood A.; Montgomery D.W.; Grant O.C.; Fuster M.M.; Fu L.; Dordick J.S.; Woods R.J.; Zhang F.; Linhardt R.J.; Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Antiviral Res 2020,181,104873","journal-title":"Antiviral Res"},{"key":"ref=96","first-page":"087288","volume":"2020","author":"Liu L.","year":"2020","unstructured":"Liu L.; Chopra P.; Li X.R.; Wolfert M.A.; Tompkins S.M.; Boons G-J.; SARS-CoV-2 spike protein binds heparan sulfate in a length- and sequence-dependent manner. bioRxiv 2020,2020,087288","journal-title":"bioRxiv"},{"key":"ref=97","first-page":"07722","volume":"2103","author":"Paiardi G.","year":"2021","unstructured":"Paiardi G.; Richter S.; Oreste P.; Urbinati C.; Rusnati M.; Wade R.C.; Three-fold mechanism of inhibition of SARS-CoV-2 infection by the interaction of the spike glycoprotein with heparin. arXiv 2021,2103,07722","journal-title":"arXiv"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijbiomac.2021.04.148","volume":"183","author":"Gupta Y.","year":"2021","unstructured":"Gupta Y.; Maciorowski D.; Zak S.E.; Kulkarni C.V.; Herbert A.S.; Durvasula R.; Fareed J.; Dye J.M.; Kempaiah P.; Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy. Int J Biol Macromol 2021,183,203-212","journal-title":"Int J Biol Macromol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"120595","DOI":"10.1016\/j.saa.2021.120595","volume":"267","author":"Li J.","year":"2022","unstructured":"Li J.; Zhang Y.; Pang H.; Li S.J.; Heparin interacts with the main protease of SARS-CoV-2 and inhibits its activity. Spectrochim Acta A Mol Biomol Spectrosc 2022,267(Pt 2),120595","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"101507","DOI":"10.1016\/j.jbc.2021.101507","volume":"298","author":"Paiardi G.","year":"2022","unstructured":"Paiardi G.; Richter S.; Oreste P.; Urbinati C.; Rusnati M.; Wade R.C.; The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms. J Biol Chem 2022,298(2),101507","journal-title":"J Biol Chem"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/cells10061419","volume":"10","author":"Partridge L.J.","year":"2021","unstructured":"Partridge L.J.; Urwin L.; Nicklin M.J.H.; James D.C.; Green L.R.; Monk P.N.; ACE2-independent interaction of SARS-CoV-2 spike protein with human epithelial cells is inhibited by unfractionated heparin. Cells 2021,10(6),1419","journal-title":"Cells"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/bph.15304","volume":"178","author":"Tree J.A.","year":"2021","unstructured":"Tree J.A.; Turnbull J.E.; Buttigieg K.R.; Elmore M.J.; Coombes N.; Hogwood J.; Mycroft-West C.J.; Lima M.A.; Skidmore M.A.; Karlsson R.; Chen Y.H.; Yang Z.; Spalluto C.M.; Staples K.J.; Yates E.A.; Gray E.; Singh D.; Wilkinson T.; Page C.P.; Carroll M.W.; Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations. Br J Pharmacol 2021,178(3),626-635","journal-title":"Br J Pharmacol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"10930","DOI":"10.1021\/acs.analchem.0c02449","volume":"92","author":"Yang Y.","year":"2020","unstructured":"Yang Y.; Du Y.; Kaltashov I.A.; The utility of native ms for understanding the mechanism of action of repurposed therapeutics in COVID-19: Heparin as a disruptor of the SARS-CoV-2 interaction with its host cell receptor. Anal Chem 2020,92(16),10930-10934","journal-title":"Anal Chem"},{"key":"ref=104","first-page":"169334","volume":"2021","author":"Guimond S.E.","year":"2021","unstructured":"Guimond S.E.; Mycroft-West C.J.; Gandhi N.S.; Tree J.A.; Le T.T.; Spalluto C.M.; Humbert M.V.; Buttigieg K.R.; Coombes N.; Elmore M.J.; Nystr\u00f6m K.; Said J.; Setoh Y.X.; Amarilla A.A.; Modhiran N.; Sng J.D.J.; Chhabra M.; Young P.R.; Lima M.A.; Yates A.E; Karlsson R; Miller R.L; Chen Y.-H; Bagdonaite I.; Yang Z.; Stewart J.; Hammond E.; Dredge K.; Wilkinson T.M.A.; Watterson D.; Khromykh A.A.; Suhrbier A.; Carroll M.W.; Trybala E.; Bergstr\u00f6m T.; Ferro V.; Skidmore M.A.; Turnbull J.E.; Pixatimod (PG545), a clinical-stage heparan sulfate mimetic, is a potent inhibitor of the SARS1-CoV-2 virus. bioRxiv 2021,2021,169334","journal-title":"bioRxiv"},{"key":"ref=105","first-page":"169334","volume":"2020","author":"Guimond S.E.","year":"2020","unstructured":"Guimond S.E.; Mycroft-West C.J.; Gandhi N.S.; Tree J.A.; Le T.T.; Spalluto C.M.; Humbert M.V.; Buttigieg K.R.; Coombes N.; Elmore M.J.; Nystr\u00f6m K.; Said J.; Setoh Y.X.; Amarilla A.A.; Modhiran N.; Sng J.D.J.; Chhabra M.; Young P.R.; Lima M.A.; Yates A.; Karlsson R; Miller R.L; Chen Y.-H; Bagdonaite I.; Yang Z.; Stewart J.; Hammond E.; Dredge K.; Wilkinson T.M.A.; Watterson D.; Khromykh A.A.; Suhrbier A.; Carroll M.W.; Trybala E.; Bergstr\u00f6m T.; Ferro V.; Skidmore M.A.; Turnbull J.E.;  Synthetic heparan sulfate mimetic pixatimod (PG545) potently inhibits SARS-CoV-2 by disrupting the spike-ACE2 interaction. bioRxiv 2020,2020,169334","journal-title":"bioRxiv"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1124\/molpharm.120.000098","volume":"98","author":"Tavassoly O.","year":"2020","unstructured":"Tavassoly O.; Safavi F.; Tavassoly I.; Heparin-binding peptides as novel therapies to stop SARS-CoV-2 cellular entry and infection. Mol Pharmacol 2020,98(5),612-619","journal-title":"Mol Pharmacol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/rth2.12353","volume":"4","author":"Liu J.","year":"2020","unstructured":"Liu J.; Li J.; Arnold K.; Pawlinski R.; Key N.S.; Using heparin molecules to manage COVID-2019. Res Pract Thromb Haemost 2020,4(4),518-523","journal-title":"Res Pract Thromb Haemost"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/s13054-020-03148-2","volume":"24","author":"van Haren F.M.P.","year":"2020","unstructured":"van Haren F.M.P.; Page C.; Laffey J.G.; Artigas A.; Camprubi-Rimblas M.; Nunes Q.; Smith R.; Shute J.; Carroll M.; Tree J.; Carroll M.; Singh D.; Wilkinson T.; Dixon B.; Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. Crit Care 2020,24(1),454","journal-title":"Crit Care"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","volume":"30","author":"Doorbar J.","year":"2012","unstructured":"Doorbar J.; Quint W.; Banks L.; Bravo I.G.; Stoler M.; Broker T.R.; Stanley M.A.; The biology and life-cycle of human papillomaviruses. Vaccine 2012,30(5)(Suppl. 5),F55-F70","journal-title":"Vaccine"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"e0199925","DOI":"10.1371\/journal.pone.0199925","volume":"13","author":"Gonzalez D.","year":"2018","unstructured":"Gonzalez D.; Ragusa J.; Angeletti P.C.; Larsen G.; Preparation and characterization of functionalized heparin-loaded poly-\u0190-caprolactone fibrous mats to prevent infection with human papillomaviruses. PLoS One 2018,13(7),e0199925","journal-title":"PLoS One"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"e1002519","DOI":"10.1371\/journal.ppat.1002519","volume":"8","author":"Surviladze Z.","year":"2012","unstructured":"Surviladze Z.; Dziduszko A.; Ozbun M.A.; Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS Pathog 2012,8(2),e1002519","journal-title":"PLoS Pathog"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"9854","DOI":"10.1021\/jp1009719","volume":"114","author":"Sun J.","year":"2010","unstructured":"Sun J.; Yu J.S.; Jin S.; Zha X.; Wu Y.; Yu Z.; Interaction of synthetic HPV-16 capsid peptides with heparin: thermodynamic parameters and binding mechanism. J Phys Chem B 2010,114(30),9854-9861","journal-title":"J Phys Chem B"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"5810","DOI":"10.1074\/jbc.274.9.5810","volume":"274","author":"Joyce J.G.","year":"1999","unstructured":"Joyce J.G.; Tung J.S.; Przysiecki C.T.; Cook J.C.; Lehman E.D.; Sands J.A.; Jansen K.U.; Keller P.M.; The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 1999,274(9),5810-5822","journal-title":"J Biol Chem"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1128\/AAC.00471-10","volume":"54","author":"Donalisio M.","year":"2010","unstructured":"Donalisio M.; Rusnati M.; Civra A.; Bugatti A.; Allemand D.; Pirri G.; Giuliani A.; Landolfo S.; Lembo D.; Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses. Antimicrob Agents Chemother 2010,54(10),4290-4299","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1128\/JVI.75.3.1565-1570.2001","volume":"75","author":"Giroglou T.","year":"2001","unstructured":"Giroglou T.; Florin L.; Sch\u00e4fer F.; Streeck R.E.; Sapp M.; Human papillomavirus infection requires cell surface heparan sulfate. J Virol 2001,75(3),1565-1570","journal-title":"J Virol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1128\/JVI.02190-08","volume":"83","author":"Johnson K.M.","year":"2009","unstructured":"Johnson K.M.; Kines R.C.; Roberts J.N.; Lowy D.R.; Schiller J.T.; Day P.M.; Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol 2009,83(5),2067-2074","journal-title":"J Virol"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"11426","DOI":"10.1128\/JVI.01721-13","volume":"87","author":"Richards K. F.","year":"2013","unstructured":"Richards K. F.; Bienkowska-Haba M.; Dasgupta J.; Chen X. S.; Sapp M.; Multiple heparan sulfate binding site engagements are required for the infectious entry of human papillomavirus type 16. J Virol 2013,87(21),11426-37","journal-title":"J Virol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.str.2016.12.001","volume":"25","author":"Guan J.","year":"2017","unstructured":"Guan J.; Bywaters S.M.; Brendle S.A.; Ashley R.E.; Makhov A.M.; Conway J.F.; Christensen N.D.; Hafenstein S.; Cryoelectron microscopy maps of human papillomavirus 16 reveal L2 densities and heparin binding site. Structure 2017,25(2),253-263","journal-title":"Structure"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.carbpol.2018.06.096","volume":"198","author":"Gao Y.","year":"2018","unstructured":"Gao Y.; Liu W.; Wang W.; Zhang X.; Zhao X.; The inhibitory effects and mechanisms of 3,6-O-sulfated chitosan against human papillomavirus infection. Carbohydr Polym 2018,198,329-338","journal-title":"Carbohydr Polym"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1462-5822.2007.01023.x","volume":"10","author":"Leistner C.M.","year":"2008","unstructured":"Leistner C.M.; Gruen-Bernhard S.; Glebe D.; Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell Microbiol 2008,10(1),122-133","journal-title":"Cell Microbiol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"e58340","DOI":"10.1371\/journal.pone.0058340","volume":"8","author":"Lamas Longarela O.","year":"2013","unstructured":"Lamas Longarela O.; Schmidt T.T.; Sch\u00f6neweis K.; Romeo R.; Wedemeyer H.; Urban S.; Schulze A.; Proteoglycans act as cellular hepatitis delta virus attachment receptors. PLoS One 2013,8(3),e58340","journal-title":"PLoS One"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/095632020201300302","volume":"13","author":"Ying C.","year":"2002","unstructured":"Ying C.; Van Pelt J.F.; Van Lommel A.; Van Ranst M.; Leyssen P.; De Clercq E.; Neyts J.; Sulphated and sulphonated polymers inhibit the initial interaction of hepatitis B virus with hepatocytes. Antivir Chem Chemother 2002,13(3),157-164","journal-title":"Antivir Chem Chemother"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1099\/vir.0.80614-0","volume":"86","author":"Zahn A.","year":"2005","unstructured":"Zahn A.; Allain J.P.; Hepatitis C virus and hepatitis B virus bind to heparin: purification of largely IgG-free virions from infected plasma by heparin chromatography. J Gen Virol 2005,86(3),677-685","journal-title":"J Gen Virol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/hep.21896","volume":"46","author":"Schulze A.","year":"2007","unstructured":"Schulze A.; Gripon P.; Urban S.; Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 2007,46(6),1759-1768","journal-title":"Hepatology"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"14461","DOI":"10.1038\/s41598-017-14573-9","volume":"7","author":"Choijilsuren G.","year":"2017","unstructured":"Choijilsuren G.; Jhou R.S.; Chou S.F.; Chang C.J.; Yang H.I.; Chen Y.Y.; Chuang W.L.; Yu M.L.; Shih C.; Heparin at physiological concentration can enhance PEG-free in vitro infection with human hepatitis B virus. Sci Rep 2017,7(1),14461","journal-title":"Sci Rep"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1039\/C8BM01134F","volume":"7","author":"Liu Q.","year":"2019","unstructured":"Liu Q.; Somiya M.; Iijima M.; Tatematsu K.; Kuroda S.; A hepatitis B virus-derived human hepatic cell-specific heparin-binding peptide: identification and application to a drug delivery system. Biomater Sci 2019,7(1),322-335","journal-title":"Biomater Sci"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"10159","DOI":"10.1128\/JVI.01180-10","volume":"84","author":"Vieyres G.","year":"2010","unstructured":"Vieyres G.; Thomas X.; Descamps V.; Duverlie G.; Patel A.H.; Dubuisson J.; Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol 2010,84(19),10159-10168","journal-title":"J Virol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/jmv.20842","volume":"79","author":"Morikawa K.","year":"2007","unstructured":"Morikawa K.; Zhao Z.; Date T.; Miyamoto M.; Murayama A.; Akazawa D.; Tanabe J.; Sone S.; Wakita T.; The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles. J Med Virol 2007,79(6),714-723","journal-title":"J Med Virol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3390\/pathogens10060685","volume":"10","author":"LeBlanc E.V.","year":"2021","unstructured":"LeBlanc E.V.; Kim Y.; Capicciotti C.J.; Colpitts C.C.; Hepatitis C.; Hepatitis C virus glycan-dependent interactions and the potential for novel preventative strategies. Pathogens 2021,10(6),685","journal-title":"Pathogens"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/jmv.10196","volume":"68","author":"Germi R.","year":"2002","unstructured":"Germi R.; Crance J.M.; Garin D.; Guimet J.; Lortat-Jacob H.; Ruigrok R.W.H.; Zarski J.P.; Drouet E.; Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol 2002,68(2),206-215","journal-title":"J Med Virol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"41003","DOI":"10.1074\/jbc.M302267200","volume":"278","author":"Barth H.","year":"2003","unstructured":"Barth H.; Sch\u00e4fer C.; Adah M.I.; Zhang F.; Linhardt R.J.; Toyoda H.; Kinoshita-Toyoda A.; Toida T.; van Kuppevelt T.H.; Depla E.; von Weizs\u00e4cker F.; Blum H.E.; Baumert T.F.; Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003,278(42),41003-41012","journal-title":"J Biol Chem"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1365-2893.2005.00647.x","volume":"12","author":"Olenina L.V.","year":"2005","unstructured":"Olenina L.V.; Kuzmina T.I.; Sobolev B.N.; Kuraeva T.E.; Kolesanova E.F.; Archakov A.I.; Identification of glycosaminoglycan-binding sites within hepatitis C virus envelope glycoprotein E2*. J Viral Hepat 2005,12(6),584-593","journal-title":"J Viral Hepat"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"10579","DOI":"10.1128\/JVI.00941-06","volume":"80","author":"Barth H.","year":"2006","unstructured":"Barth H.; Schnober E.K.; Zhang F.; Linhardt R.J.; Depla E.; Boson B.; Cosset F.L.; Patel A.H.; Blum H.E.; Baumert T.F.; Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol 2006,80(21),10579-10590","journal-title":"J Virol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1128\/JVI.02622-06","volume":"81","author":"Basu A.","year":"2007","unstructured":"Basu A.; Kanda T.; Beyene A.; Saito K.; Meyer K.; Ray R.; Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells. J Virol 2007,81(8),3933-3941","journal-title":"J Virol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10719-012-9388-z","volume":"29","author":"Kobayashi F.","year":"2012","unstructured":"Kobayashi F.; Yamada S.; Taguwa S.; Kataoka C.; Naito S.; Hama Y.; Tani H.; Matsuura Y.; Sugahara K.; Specific interaction of the envelope glycoproteins E1 and E2 with liver heparan sulfate involved in the tissue tropismatic infection by hepatitis C virus. Glycoconj J 2012,29(4),211-220","journal-title":"Glycoconj J"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"7256","DOI":"10.1128\/JVI.07222-11","volume":"86","author":"Jiang J.","year":"2012","unstructured":"Jiang J.; Cun W.; Wu X.; Shi Q.; Tang H.; Luo G.; Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol 2012,86(13),7256-7267","journal-title":"J Virol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"e67982","DOI":"10.1371\/journal.pone.0067982","volume":"8","author":"Jiang J.","year":"2013","unstructured":"Jiang J.; Wu X.; Tang H.; Luo G.; Apolipoprotein E mediates attachment of clinical hepatitis C virus to hepatocytes by binding to cell surface heparan sulfate proteoglycan receptors. PLoS One 2013,8(7),e67982","journal-title":"PLoS One"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1128\/JVI.03647-14","volume":"89","author":"Xu Y.","year":"2015","unstructured":"Xu Y.; Martinez P.; S\u00e9ron K.; Luo G.; Allain F.; Dubuisson J.; Belouzard S.; Characterization of hepatitis C virus interaction with heparan sulfate proteoglycans. J Virol 2015,89(7),3846-3858","journal-title":"J Virol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1021\/jm100078r","volume":"53","author":"Chavas L.M.G.","year":"2010","unstructured":"Chavas L.M.G.; Kato R.; Suzuki N.; von Itzstein M.; Mann M.C.; Thomson R.J.; Dyason J.C.; McKimm-Breschkin J.; Fusi P.; Tringali C.; Venerando B.; Tettamanti G.; Monti E.; Wakatsuki S.; Complexity in influenza virus targeted drug design: interaction with human sialidases. J Med Chem 2010,53(7),2998-3002","journal-title":"J Med Chem"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"11660","DOI":"10.1038\/s41598-017-12012-3","volume":"7","author":"Foni E.","year":"2017","unstructured":"Foni E.; Chiapponi C.; Baioni L.; Zanni I.; Merenda M.; Rosignoli C.; Kyriakis C. S.; Luini M. V.; Mandola M. L.; Bolzoni L.; Nigrelli A. D.; Faccini S.; Influenza D in Italy: towards a better understanding of an emerging viral infection in swine. Sci Rep-Uk 2017,7(1),11660","journal-title":"Sci Rep-Uk"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1039\/C4MD00516C","volume":"6","author":"Skidmore M.A.","year":"2015","unstructured":"Skidmore M.A.; Kajaste-Rudnitski A.; Wells N.M.; Guimond S.E.; Rudd T.R.; Yates E.A.; Vicenzi E.; Inhibition of influenza H5N1 invasion by modified heparin derivatives. MedChemComm 2015,6(4),640-646","journal-title":"MedChemComm"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/08977194.2021.1895144","volume":"38","author":"Lai K.M.","year":"2020","unstructured":"Lai K.M.; Goh B.H.; Lee W.L.; Attenuating influenza a virus infection by heparin binding EGF-like growth factor. Growth Factors 2020,38(3-4),167-176","journal-title":"Growth Factors"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jsb.2008.12.002","volume":"165","author":"Levy H.C.","year":"2009","unstructured":"Levy H.C.; Bowman V.D.; Govindasamy L.; McKenna R.; Nash K.; Warrington K.; Chen W.; Muzyczka N.; Yan X.; Baker T.S.; Agbandje-McKenna M.; Heparin binding induces conformational changes in Adeno-associated virus serotype 2. J Struct Biol 2009,165(3),146-156","journal-title":"J Struct Biol"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"6909","DOI":"10.1128\/JVI.76.14.6909-6918.2002","volume":"76","author":"Walker S.J.","year":"2002","unstructured":"Walker S.J.; Pizzato M.; Takeuchi Y.; Devereux S.; Heparin binds to murine leukemia virus and inhibits Env-independent attachment and infection. J Virol 2002,76(14),6909-6918","journal-title":"J Virol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"e00432-17","DOI":"10.1128\/JVI.00432-17","volume":"91","author":"Tanaka A.","year":"2017","unstructured":"Tanaka A.; Tumkosit U.; Nakamura S.; Motooka D.; Kishishita N.; Priengprom T.; Sa-ngasang A.; Kinoshita T.; Takeda N.; Maeda Y.; Genome-wide screening uncovers the significance of N-sulfation of heparan sulfate as a host cell factor for chikungunya virus infection. J Virol 2017,91(13),e00432-17","journal-title":"J Virol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"BSR20191077","DOI":"10.1042\/BSR20191077","volume":"39","author":"Sahoo B.","year":"2019","unstructured":"Sahoo B.; Chowdary T.K.; Conformational changes in Chikungunya virus E2 protein upon heparan sulfate receptor binding explain mechanism of E2\u2013E1 dissociation during viral entry. Biosci Rep 2019,39(6),BSR20191077","journal-title":"Biosci Rep"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"e01500-20","DOI":"10.1128\/JVI.01500-20","volume":"94","author":"McAllister N.","year":"2020","unstructured":"McAllister N.; Liu Y.; Silva L.M.; Lentscher A.J.; Chai W.; Wu N.; Griswold K.A.; Raghunathan K.; Vang L.; Alexander J.; Warfield K.L.; Diamond M.S.; Feizi T.; Silva L.A.; Dermody T.S.; Chikungunya virus strains from each genetic clade bind sulfated glycosaminoglycans as attachment factors. J Virol 2020,94(24),e01500-20","journal-title":"J Virol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12985-019-1246-1","volume":"16","author":"Wu S.","year":"2019","unstructured":"Wu S.; Wu Z.; Wu Y.; Wang T.; Wang M.; Jia R.; Zhu D.; Liu M.; Zhao X.; Yang Q.; Wu Y.; Zhang S.; Liu Y.; Zhang L.; Yu Y.; Pan L.; Chen S.; Cheng A.; Heparin sulfate is the attachment factor of duck Tembus virus on both BHK21 and DEF cells. Virol J 2019,16(1),134","journal-title":"Virol J"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1128\/JVI.01621-12","volume":"87","author":"Salvador B.","year":"2013","unstructured":"Salvador B.; Sexton N.R.; Carrion R.; Nunneley J.; Patterson J.L.; Steffen I.; Lu K.; Muench M.O.; Lembo D.; Simmons G.; Filoviruses utilize glycosaminoglycans for their attachment to target cells. J Virol 2013,87(6),3295-3304","journal-title":"J Virol"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12985-018-1045-0","volume":"15","author":"Tamhankar M.","year":"2018","unstructured":"Tamhankar M.; Gerhardt D.M.; Bennett R.S.; Murphy N.; Jahrling P.B.; Patterson J.L.; Heparan sulfate is an important mediator of Ebola virus infection in polarized epithelial cells. Virol J 2018,15(1),135","journal-title":"Virol J"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1006\/viro.2001.0986","volume":"286","author":"Su C.M.","year":"2001","unstructured":"Su C.M.; Liao C.L.; Lee Y.L.; Lin Y.L.; Highly sulfated forms of heparin sulfate are involved in japanese encephalitis virus infection. Virology 2001,286(1),206-215","journal-title":"Virology"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.antiviral.2008.08.006","volume":"80","author":"Terao-Muto Y.","year":"2008","unstructured":"Terao-Muto Y.; Yoneda M.; Seki T.; Watanabe A.; Tsukiyama-Kohara K.; Fujita K.; Kai C.; Heparin-like glycosaminoglycans prevent the infection of measles virus in SLAM-negative cell lines. Antiviral Res 2008,80(3),370-376","journal-title":"Antiviral Res"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s00705-015-2408-0","volume":"160","author":"Huan C.","year":"2015","unstructured":"Huan C.; Wang Y.; Ni B.; Wang R.; Huang L.; Ren X.; Tong G.; Ding C.; Fan H.; Mao X.; Porcine epidemic diarrhea virus uses cell-surface heparan sulfate as an attachment factor. Arch Virol 2015,160(7),1621-1628","journal-title":"Arch Virol"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1093\/infdis\/jiy081","volume":"217","author":"Sasaki M.","year":"2018","unstructured":"Sasaki M.; Anindita P.D.; Ito N.; Sugiyama M.; Carr M.; Fukuhara H.; Ose T.; Maenaka K.; Takada A.; Hall W.W.; Orba Y.; Sawa H.; The role of heparan sulfate proteoglycans as an attachment factor for rabies virus entry and infection. J Infect Dis 2018,217(11),1740-1749","journal-title":"J Infect Dis"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3390\/v11070593","volume":"11","author":"Ke F.","year":"2019","unstructured":"Ke F.; Wang Z.H.; Ming C.Y.; Zhang Q.Y.; Ranaviruses bind cells from different species through interaction with heparan sulfate. Viruses 2019,11(7),593","journal-title":"Viruses"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.virol.2005.11.034","volume":"347","author":"Bear J.S.","year":"2006","unstructured":"Bear J.S.; Byrnes A.P.; Griffin D.E.; Heparin-binding and patterns of virulence for two recombinant strains of Sindbis virus. Virology 2006,347(1),183-190","journal-title":"Virology"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1096\/fj.10-177188","volume":"25","author":"Montanuy I.","year":"2011","unstructured":"Montanuy I.; Alejo A.; Alcami A.; Glycosaminoglycans mediate retention of the poxvirus type I interferon binding protein at the cell surface to locally block interferon antiviral responses. FASEB J 2011,25(6),1960-1971","journal-title":"FASEB J"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"10524","DOI":"10.3390\/ijms221910524","volume":"22","author":"Banik N.","year":"2021","unstructured":"Banik N.; Yang S.B.; Kang T.B.; Lim J.H.; Park J.; Heparin and its derivatives: challenges and advances in therapeutic biomolecules. Int J Mol Sci 2021,22(19),10524","journal-title":"Int J Mol Sci"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.3390\/ijms20205092","volume":"20","author":"Torres F.G.","year":"2019","unstructured":"Torres F.G.; Troncoso O.P.; Pisani A.; Gatto F.; Bardi G.; Natural polysaccharide nanomaterials: an overview of their immunological properties. Int J Mol Sci 2019,20(20),5092","journal-title":"Int J Mol Sci"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.3390\/ijms22084077","volume":"22","author":"Qiu X.L.","year":"2021","unstructured":"Qiu X.L.; Fan Z.R.; Liu Y.Y.; Wang D.F.; Wang S.X.; Li C.X.; Preparation and evaluation of a self-nanoemulsifying drug delivery system loaded with heparin phospholipid complex. Int J Mol Sci 2021,22(8),4077","journal-title":"Int J Mol Sci"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/jbm.a.36815","volume":"108","author":"Wan X.","year":"2020","unstructured":"Wan X.; Li P.; Jin X.; Su F.; Shen J.; Yuan J.; Poly(\u03b5- caprolactone)\/keratin\/heparin\/VEGF biocomposite mats for vascular tissue engineering. J Biomed Mater Res A 2020,108(2),292-300","journal-title":"J Biomed Mater Res A"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.antiviral.2016.09.012","volume":"135","author":"Pitt E.A.","year":"2016","unstructured":"Pitt E.A.; Dogra P.; Patel R.S.; Williams A.; Wall J.S.; Sparer T.E.; The D-form of a novel heparan binding peptide decreases cytomegalovirus infection in vivo and in vitro. Antiviral Res 2016,135,15-23","journal-title":"Antiviral Res"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1096\/fba.2020-00015","volume":"2","author":"Hondermarck H.","year":"2020","unstructured":"Hondermarck H.; Bartlett N.W.; Nurcombe V.; The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID-19? FASEB Bioadv 2020,2(5),296-303","journal-title":"FASEB Bioadv"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nrm1681","volume":"6","author":"H\u00e4cker U.","year":"2005","unstructured":"H\u00e4cker U.; Nybakken K.; Perrimon N.; Heparan sulphate proteoglycans: the sweet side of development. Nat Rev Mol Cell Biol 2005,6(7),530-541","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"103300","DOI":"10.1016\/j.retram.2021.103300","volume":"69","author":"Chen D.","year":"2021","unstructured":"Chen D.; Heparin beyond anti-coagulation. Curr Res Transl Med 2021,69(4),103300-103303","journal-title":"Curr Res Transl Med"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nrd1067","volume":"2","author":"Goldberg M.","year":"2003","unstructured":"Goldberg M.; Gomez-Orellana I.; Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov 2003,2(4),289-295","journal-title":"Nat Rev Drug Discov"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"640","DOI":"10.2174\/1389201015666140915151649","volume":"15","author":"Schl\u00fcter A.","year":"2014","unstructured":"Schl\u00fcter A.; Lamprecht A.; Current developments for the oral delivery of heparin. Curr Pharm Biotechnol 2014,15(7),640-649","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ajps.2019.11.006","volume":"15","author":"Fang G.","year":"2020","unstructured":"Fang G.; Tang B.; Advanced delivery strategies facilitating oral absorption of heparins. Asian J Pharmaceut Sci 2020,15(4),449-460","journal-title":"Asian J Pharmaceut Sci"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1093\/biolre\/ioy127","volume":"99","author":"Wat J.M.","year":"2018","unstructured":"Wat J.M.; Hawrylyshyn K.; Baczyk D.; Greig I.R.; Kingdom J.C.; Effects of glycol-split low molecular weight heparin on placental, endothelial, and anti-inflammatory pathways relevant to preeclampsia. Biol Reprod 2018,99(5),1082-1090","journal-title":"Biol Reprod"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"628551","DOI":"10.3389\/fmolb.2020.628551","volume":"7","author":"Yu M.","year":"2021","unstructured":"Yu M.; Zhang T.; Zhang W.; Sun Q.; Li H.; Li J.; Elucidating the interactions between heparin\/heparan sulfate and SARS-CoV-2-related proteins\u2014an important strategy for developing novel therapeutics for the COVID-19 pandemic. Front Mol Biosci 2021,7,628551-628563","journal-title":"Front Mol Biosci"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230203124032","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/213424\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230203124032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T10:51:01Z","timestamp":1695811861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/213424\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":170,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867330666230203124032","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-04-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}